行业评级：看好（维持） 证券研究报告|行业专题报告 美容护理 2026年1月12日 国产替代趋势延续，优质国货凸显强α --美护行业2026年度投资策略 证券分析师 姓名：丁一 S1350524040003 dingyi@huayuanstock.com 联系人 姓名：王悦 wangyue03@huayuanstock.com 请务必仔细阅读正文之后的评级说明和重要声明 报告要点 n 2025年行业发展回顾 n 2026年行业机会展望 n 投资建议 Ø 我们认为国货龙头仍有望凭借品牌营销+产品矩阵+渠道策略+管理战略多重优势持续强势领跑，持续看好美护板块优质标的高成长性。建议关 注：1）强品牌势能标的：毛戈平，高端美妆国货龙头，产品及渠道持续破圈；丸美生物，大单品势能持续释放，品牌加速成长；珀莱雅，组织 架构成熟+大单品、营销及管理能力均处于行业领先；若羽臣，自有品牌高速增长，持续释放业绩；2）受益平价消费趋势标的：上美股份，多 品类多渠道协同发展，高基数下销售超预期表现；润本股份，驱蚊&婴童赛道优质国货，自身经营优秀、产品与渠道成长确定性较强。 n 风险提示 Ø 政策变动风险；行业竞争加剧风险；电商渠道竞争 ...

1月8日，爱美客公告，其经销的注射用A型肉毒毒素产品获得国家药品监督管理局核准签发的《药品注 册证书》。 智通财经记者 | 李科文 智通财经编辑 | 谢欣 这是爱美客首款注射用A型肉毒毒素产品，也是国内第七款。1月9日，智通财经记者联系爱美客，截至 发稿未获回复。 爱美客肉毒素布局起于2021年。 2021年，爱美客以8.56亿元收购韩国医美公司Huons BioPharma 25.42%的股权。 Huons BioPharma原是韩国上市公司Huons Global Co., Ltd.的肉毒毒素等生物制品业务部门。Huons Global分拆肉毒毒素等生物制品业务部门并成立了如今的Huons BioPharma。 2022年5月，爱美客以研发注册方式引进Huons BioPharma生产的注射用A型肉毒毒素产品，并在约定经 销区域内作为Huons BioPharma指定的唯一且排他的进口商、经销商。 肉毒素能否接力成为爱美客的第三增长点，目前仍存在较大不确定性。 与此前在再生医美赛道中抢占第一梯队不同，爱美客此次推出的产品，已是国内第七款同类产品。 在此之前，我国合规上市的肉毒素产品已有6款，分别包括美国艾 ...

Group 1 - The core viewpoint of the article highlights the recent management change at Aimeike Technology Development Co., Ltd., with Li Dongmei appointed as the new Deputy General Manager and Board Secretary during a challenging period for the company [2] - Aimeike is facing significant challenges, with a reported revenue of 1.865 billion yuan for the first three quarters of 2025, representing a year-on-year decline of 21.49%, and a net profit of 1.093 billion yuan, down 31.05% year-on-year [3] - The decline in performance is attributed to intensified industry competition, particularly from Huaxi Biological's competing product "Runzhi·Gegge," which is affecting Aimeike's core product "Haitai" [3] Group 2 - Aimeike is embroiled in a dispute over the agency rights of its product AestheFill, which has escalated to a trademark infringement case involving a compensation claim of 1.6 billion yuan [4] - The appointment of a legal professional as a senior executive suggests that Aimeike aims to enhance its compliance, risk management, and arbitration dispute response capabilities [4] - Li Dongmei's nearly twenty years of legal experience is expected to provide professional support to Aimeike in navigating its current challenges [4]

Group 1 - The company has completed the acquisition of a controlling stake in REGEN, with the domestic product "Zhen Ai Su Fei" already launched for sale, and attention is on the sales ramp-up during the transition period [1] - The company has received approval for Minoxidil topical solution, and it is expected that 2026 will see a concentrated launch of new pipelines such as botulinum toxin, with a focus on the progress of these new products in the domestic market [1] - The company has completed its first cosmetic raw material filing, with the core ingredient "Glycyrrhetinic Acid A" sourced from the Chinese herb licorice, which can be used as a skin protectant and moisturizer in cosmetics [1] Group 2 - The traditional product segment is under short-term pressure due to low market sentiment and intensified competition, with Q3 revenue expected to continue its downward trend [2] - For the first three quarters of 2025, revenue was 1.865 billion, down 21.49%, and net profit attributable to the parent company was 1.093 billion, down 31.05% [2] - In Q3 2025, revenue was 566 million, down 21.27%, and net profit attributable to the parent company was 304 million, down 34.61% [2] Group 3 - The company’s performance remains under pressure due to low industry sentiment and increased competition, with a focus on the sales ramp-up of "Zhen Ai Su Fei" during the transition period [3] - The new REGEN factory in South Korea has successfully commenced production, expected to release incremental capacity this year and expand into markets in the Middle East and Southeast Asia [3] - The company is anticipated to experience a concentrated launch of new pipelines in 2026, with attention on the progress of these new products and their market release rhythm [3]

Core Viewpoint - Aimeike, once a leading player in the medical beauty industry, is facing significant challenges with declining performance and ongoing disputes over product agency rights, prompting a recent board reshuffle to address these issues [2][3][20]. Company Overview - Aimeike's actual controller, Jian Jun, has been re-elected as chairman, with a stable core management team, while the new board secretary, Li Dongmei, is seen as a fresh face amid the company's current challenges [2]. - The company has experienced a dramatic decline in performance, with a first-time negative growth reported in the first half of 2025, and significant year-on-year drops in revenue and net profit [3][13]. Financial Performance - In the third quarter of 2025, Aimeike reported revenue of 566 million yuan and a net profit of 304 million yuan, representing declines of 21.27% and 34.61% year-on-year, respectively [3]. - As of November 21, 2025, Aimeike's stock price is 148 yuan per share, with a market capitalization of 44.8 billion yuan, down over 100 billion yuan from its peak [4]. - The company's financial struggles have also impacted Jian Jun's wealth, which has decreased significantly over the past two years [6]. Historical Growth Trajectory - Aimeike's growth trajectory has been closely tied to its innovative product development, with significant milestones including the launch of its first self-developed product in 2009 and the introduction of several key products that drove revenue growth [9][10]. - The company saw explosive growth from 2021 to 2023, with revenues increasing from 1.448 billion yuan in 2021 to 2.869 billion yuan in 2023, and net profits rising from 958 million yuan to 1.858 billion yuan during the same period [7][10]. Current Challenges - The company is now facing a decline in growth momentum, with projections for 2024 showing single-digit growth rates, and a significant drop in revenue and net profit in the first half of 2025 [13]. - The decline is attributed to the weakening performance of its core products, particularly the HiTi and Luhua Tianzi, which have seen substantial year-on-year revenue declines [13][14]. Market Competition - The competitive landscape in the medical beauty industry is intensifying, with new entrants and increased product offerings leading to a dilution of Aimeike's previous competitive advantages [14][19]. - The recent launch of competing products has further pressured Aimeike's market share, particularly in the neck wrinkle treatment segment [13][14]. Strategic Responses - In response to these challenges, Aimeike is focusing on diversifying its product offerings and enhancing its research and development capabilities, including the introduction of new products and expansion into biopharmaceuticals [15][17]. - The company has also pursued strategic acquisitions, such as the purchase of a majority stake in REGEN, to bolster its product portfolio and enhance its competitive position in the global market [17][18]. Agency Dispute - Aimeike is embroiled in a significant dispute over the agency rights for its AestheFill product, which has led to legal actions and could impact its market performance [18][20]. - The resolution of this dispute is critical for Aimeike's management team, as it seeks to stabilize the company amid declining market conditions and increasing competition [20].

Core Viewpoint - Aimeike, once a leading player in the medical beauty industry, is facing significant challenges with declining performance and ongoing disputes over product agency rights, prompting a leadership change and strategic reassessment [4][6][20]. Company Overview - Aimeike's stock price peaked at 1331 yuan in February 2021, with a market capitalization exceeding 150 billion yuan, earning it the nickname "the Moutai of women" [4]. - The company has seen a dramatic decline in performance, with a 21.27% drop in revenue and a 34.61% drop in net profit in Q3 2025 compared to the previous year [6][8]. Financial Performance - Aimeike's financial performance over the past five years shows a significant decline, with 2025 projections indicating a drop in revenue and net profit by over 20% [9][13]. - The company's revenue and net profit for 2025 are expected to be 18.65 billion yuan and 10.93 billion yuan, respectively, marking a substantial decrease from previous years [9][13]. Product Development and Market Position - Aimeike's growth was initially driven by innovative products like the "Hi Body" and "Moisturizing Angel," which captured significant market share [10][11]. - However, competition has intensified, particularly in the high-end segment, leading to a dilution of the unique advantages of core products [12][14]. Strategic Response - In response to market challenges, Aimeike is diversifying its product offerings and has initiated a shift towards biopharmaceuticals and chemical drugs [15]. - The company has also pursued acquisitions, such as the purchase of a majority stake in REGEN, to enhance its product portfolio and market competitiveness [17][18]. Agency Dispute - Aimeike is embroiled in a significant dispute over the agency rights for its product AestheFill, which has implications for its market strategy and financial performance [18][19]. - The resolution of this dispute is critical for Aimeike's management to demonstrate their capability to navigate challenges and restore growth [20].

Core Viewpoint - Aimeike, once a leading player in the medical beauty industry, is facing significant challenges with declining performance and ongoing disputes over product agency rights, leading to a critical management transition [1][2]. Group 1: Company Performance - In the first half of 2025, Aimeike reported its first negative growth, with Q3 revenue at 566 million yuan and net profit at 304 million yuan, down 21.27% and 34.61% year-on-year, respectively [2]. - The company's market capitalization has dropped to approximately 45 billion yuan, a decline of over 100 billion yuan from its peak [2]. - The core products, including the solution-based injection products and gel-based injection products, have seen revenue declines of 23.79% and 23.99% respectively in the first half of 2025 [6]. Group 2: Management Changes - The recent board reshuffle saw Jian Jun re-elected as chairman, while the resignation of the board secretary, Jian Yong, and the appointment of Li Dongmei as the new secretary raised market interest [1][2]. - The new management faces the challenge of addressing the company's declining performance and resolving the ongoing agency disputes [2][12]. Group 3: Product Development and Market Dynamics - Aimeike's growth was initially driven by innovative products, such as the first domestically developed hyaluronic acid injection, which captured significant market share [3][4]. - The company has expanded its product matrix, with gel-based products showing substantial growth, achieving revenue of 1.158 billion yuan in 2023, a year-on-year increase of 81.43% [5]. - However, increased competition in the medical beauty sector has diluted the uniqueness of Aimeike's core products, leading to a more challenging market environment [6][7]. Group 4: Strategic Initiatives - Aimeike is pursuing diversification in its product offerings, including the launch of new products like the medical-grade polyethylene glycol gel [8]. - The company has also engaged in strategic acquisitions, such as the 190 million USD purchase of a majority stake in REGEN, to enhance its product portfolio and market competitiveness [9][10]. Group 5: Agency Disputes - Aimeike is embroiled in a significant agency dispute over the AestheFill product, which has implications for its market strategy and financial performance [10][11]. - The conflict escalated with the termination of the exclusive distribution agreement by Jiangsu Wuzhong, leading to potential legal ramifications and financial claims [11][12]. - The resolution of this dispute is critical for Aimeike's management to demonstrate its capability to navigate challenges and restore growth [13].

Core Viewpoint - Aimeike, once a leading player in the medical beauty industry, is facing significant challenges with declining performance and ongoing disputes over product agency rights, prompting a recent board reshuffle to address these issues [1][2][6]. Company Overview - Aimeike's actual controller, Jian Jun, was re-elected as chairman, while the management team remains stable, with Li Dongmei being promoted to a key role amid the company's current challenges [1][2]. - The company has seen a drastic decline in stock price and market capitalization, dropping from a peak of over 150 billion yuan to around 45 billion yuan [2][6]. Financial Performance - In the first half of 2025, Aimeike reported a revenue of 5.66 billion yuan and a net profit of 3.04 billion yuan, marking declines of 21.27% and 34.61% year-on-year, respectively [2][6]. - The company experienced its first negative growth in 2025, with revenue and net profit both declining over 20% [6][7]. Product Development and Market Position - Aimeike's growth has been closely tied to its innovative product development, with key products like "HiTi" and "Luhua Tianzi" driving significant revenue [3][5]. - The company has expanded its product matrix, with "HiTi" achieving a revenue share increase from 15.34% in 2017 to 43.5% in 2019 [4]. Competitive Landscape - The medical beauty industry is undergoing rapid changes, with increased competition leading to a dilution of Aimeike's product advantages, particularly for "HiTi" and "Luhua Tianzi" [7][8]. - New entrants in the market have intensified competition, with the number of approved "童颜针" products increasing to seven, further squeezing Aimeike's growth potential [8][9]. Strategic Initiatives - Aimeike is diversifying its product offerings, including the launch of new products like "Kela" and expanding into biopharmaceuticals and chemical drugs [9][10]. - The company has also pursued acquisitions, such as the purchase of a majority stake in REGEN, to enhance its product portfolio and market competitiveness [10][11]. Legal and Regulatory Challenges - Aimeike is embroiled in a significant dispute over the agency rights for its product "AestheFill," which could impact its market performance and brand partnerships [11][12]. - The ongoing arbitration with Jiangsu Wuzhong over the exclusive distribution rights of "AestheFill" highlights the complexities of brand ownership and distribution in the medical beauty sector [12][15].

Core Viewpoint - Aimeike, once hailed as the "beauty medical leader," is facing severe challenges since its IPO, with continuous declines in both revenue and net profit over four consecutive quarters, reflecting deeper operational crises amid intensified market competition [1][2][4]. Financial Performance - In Q3 2025, Aimeike's revenue decreased by 21.27% year-on-year to 1.865 billion yuan, while net profit attributable to shareholders fell by 34.61% to 1.093 billion yuan [2][4]. - The company has experienced a downward trend in revenue and net profit since Q4 2024, with respective declines of 7%, 17.9%, 25.11%, and 21.27% for revenue, and 15.47%, 15.87%, 41.75%, and 34.61% for net profit in the last four quarters [4][6]. Inventory and Efficiency - Aimeike's inventory scale has been increasing, with a 41.66% year-on-year growth in inventory size to 96 million yuan in the first three quarters of 2025, while inventory turnover efficiency has significantly declined, with turnover days extending to 185 days, an increase of 56 days compared to the previous year [6][7]. Product Performance - The decline in Aimeike's performance is primarily attributed to the poor sales of its two core products: solution and gel injection products, which saw revenue drops of 23.79% and 23.99% respectively in the first half of 2025 [6][7]. Strategic Acquisitions - To seek growth, Aimeike has engaged in high-premium acquisitions, including a notable acquisition of REGEN Biotech for approximately 1.9 billion USD, which resulted in a significant increase in goodwill to about 1.651 billion yuan [7][10]. - The acquisition has led to legal complications, including a 1.6 billion yuan arbitration case related to the exclusive distribution rights of AestheFill, a key product from REGEN [10][11]. Market Dynamics - The injection beauty market in China is characterized by high competition and increasing numbers of approved products, which has diminished Aimeike's first-mover advantage in the hyaluronic acid injection sector [7][8]. - The company has been actively expanding its product line through mergers and acquisitions to maintain its competitive edge in the injection beauty field [8][9].

Investment Rating - The investment rating for the company is "Buy" and is maintained [8]. Core Views - In Q3 2025, the company achieved operating revenue of 566 million yuan, a year-on-year decrease of 21.27%. The net profit attributable to the parent company was 304 million yuan, down 34.61% year-on-year, while the net profit excluding non-recurring items was 255 million yuan, a decline of 42.37% year-on-year [2][6]. - The revenue decline has narrowed sequentially due to the consolidation of REGEN Company, with revenue declines in Q1, Q2, and Q3 being 17.9%, 25.11%, and 21.27% respectively. The main reason for the narrowing decline is the lower revenue base starting from Q3 of the previous year [11]. - The company's gross profit margin for Q3 was 93.2%, a year-on-year decrease of 1.4 percentage points, while the net profit margin attributable to the parent company was 53.7%, down 11 percentage points year-on-year. This decline in profitability is attributed to revenue pressure and relatively rigid expense inputs [11]. - The internationalization strategy is expected to bring new growth. The consolidation of REGEN has introduced products that complement the existing product matrix, enhancing the company's offerings in the aesthetic medicine sector [11]. - The company forecasts EPS for 2025, 2026, and 2027 to be 4.92 yuan, 5.62 yuan, and 6.20 yuan respectively, indicating a positive outlook despite current pressures [11]. Financial Summary - For 2025, the company expects total revenue of 2.515 billion yuan, with a gross profit of 2.345 billion yuan, resulting in a gross margin of 93% [17]. - The projected net profit for 2025 is 1.489 billion yuan, with an EPS of 4.92 yuan [17]. - The company’s cash flow from operating activities is expected to be 1.499 billion yuan in 2025 [17].